Heart Failure Society of America Annual Meeting

A study presented at HFSA 2023 offers clinicians an overview of the influence of socioeconomic status on access to implantable hemodynamic monitors using the National Inpatient Sample.

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.

DELTA-HF trial: Device-based thoracic duct decompression with the eLym system could prove beneficial in acute decompensated heart failure patients.

The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.

Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.

A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.

José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.

Lauren Eyadiel, MMS, PA-C, offers insight into a presentation from HFSA 2023 examining strategies for overcoming financial barriers to GDMT optimization in heart failure.

Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

While better therapies exist to treat patients with heart failure with reduced ejection fraction, there are several hurdles preventing them from being implemented.

Doctors need to use their best judgement when deciding when to use cardiogenic shock devices for temporary mechanical support.

How recent trends in heart failure research have shown more priority to patient quality of life outcomes.

How does the broadened sacubitril/valsartan assessment influence the treating confidence of a clinician?

Shaquille O'Neal, EdD, and Elizabeth Ofili, MD, discuss how organizations and physicians are taking novel approaches to engage patients and non-patients about heart failure.

New findings from the trial show daily adherence to the fluid monitoring ReDS system dropped HF patient readmission risk by 58%.

Shaquille O'Neal and Elizabeth Ofili, MD, sit down to discuss Shaq Gets Real, which is a new campaign from Arbor Pharmaceuticals to increase awareness of the disparities in heart failure rates in the African American community.

After success in a recent clinical trial, dapagliflozin will soon be available to reduce the risk of heart failure in adults with heart failure reduced ejection fraction or preserved ejection fraction.

Elizabeth Ofili, MD, discusses the importance of annual meetings, such as HFSA 2019, for outreach and engaging patient populations about heart failure.

At the annual meeting dedicated to heart failure, investigators present nutritional recommendations for patients, which includes dietary consultations, bariatric surgery, and a reduction in saturated fats and sodium.

Shaquille O'Neal, Ed.D, and Elizabeth Ofili, MD, discuss using unconventional mediums to engage non-patients and spread awarness of heart failure — specifically in African Americans.

A proof of concept trial examining spironolactone for heart failure prevention presented at HFSA 2019 found spironolactone use did reduce PIIINP or that its impact on PIIINP was mitigated by galectin-3.

There are many options to treat heart failure for patients suffering from end stage kidney disease.

Results of the AMBER study, presented at HFSA 2019, found that patiromer can help improve spironolactone use while also reducing the prevalence of hyperkalemia.

While the benefits are clear, there are still some hurdles that remain preventing an increase in suggested dialysis frequency.

What was learned from the newest data for sacubitril/valsartan for HFrEF?